P090: Staging of Lung Lesions Survey Demonstrates Continued Need for Harmonization

por Seelisch, Jennifer, Kaste, Sue C., Kelly, Kara M., Kurch, Lars, Link, Michael P., Mauz-Koerholz, Christine, Mccarten, Kathleen, Punnett, Angela, Stroevesandt, Dietrich, Flerlage, Jamie E.
Publicado 2022

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma

por Visentin, Andrea, Ruggeri, Edoardo, Frezzato, Federica, Pizzi, Marco, Cellini, Alessandro, Angotzi, Francesco, Cavarretta, Chiara Adele, Ruocco, Valeria, Pravato, Stefano, Severin, Filippo, Facco, Monica, Manni, Sabrina, Piazza, Francesci, Trentin, Livio
Publicado 2022

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial

por Oertel, Michael, Hering, Dominik, Nacke, Nina, Kittel, Christopher, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Engert, Andreas, Haverkamp, Uwe, Eich, Hans Theodor
Publicado 2022

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.

por Mangasarova, Ya.K., Moiseeva, T.N., Al-Radi, L.S., Margolin, O.V., Gorenkova, L.G., Nesterova, E.S., Bagova, M.O., Fastova, E.A., Abdurashidova, R.R., Sarakaeva, Z.T., Dorokhina, Elena, Kravchenko, S.K., Magomedova, A.U., Zvonkov, E.E.
Publicado 2022

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma

por Müller-Meinhard, Berit, Reinke, Sarah, Seifert, Nicole, Engert, Andreas, Bröckelmann, Paul J., Altenbuchinger, Michael, Klapper, Wolfram
Publicado 2022

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

por Van Heek, Lutz, Stuka, Colin, Kaul, Helen, Müller, Horst, Mettler, Jasmin, Hitz, Felicitas, Baues, Christian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, Dietlein, Markus, Voltin, Conrad-Amadeus, Kobe, Carsten
Publicado 2022

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clini...

por Jain, Hasmukh, Singh, Ajay, Sengar, Manju, Eipe, Thomas, Mehta, Hiral, Bagal, Bhausaheb, Thorat, Jayashree, Nayak, Lingaraj, Sharma, Neha
Publicado 2022

P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma

por Geurts, Yvonne M.G., Shakir, Rebecca, Ntentas, Georgios, Roberti, Sander, Aznar, Marianne, John, Katinka, Ramroth, Johanna, Janus, Cécile P.M., Krol, Augustinus, Roesink, Judith, Van Der Maazen, Richard W.M., Zijlstra, Josée. M., Darby, Sarah, Aleman, Berthe M. P., Van Leeuwen, Flora E., Cutter, David, Schaapveld, Michael
Publicado 2022

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

por Voltin, Conrad-Amadeus, Kreissl, Stefanie, Kaul, Helen, Bühnen, Ina, Mettler, Jasmin, Pabst, Thomas, Eichenauer, Dennis A., Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, Borchmann, Peter, Kobe, Carsten
Publicado 2022

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma

por Moatti, Hannah, Laroque, Marie-Céleste, Renaud, Loïc., Ravdan, Odonchimeg, Schmidt-Hieber, Charlotte, Madelaine, Isabelle, Di Blasi, Roberta, Thieblemont, Catherine, Brice, Pauline
Publicado 2022

P029: Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?

por M’Kacher, Radhia, Junker, Steffen, Colicchio, Bruno, Najar, Wala, Mika, Justyna, Dieterlen, Alain, Polanska, Joanna, Voisin, Philippe, Jeandidier, Eric, Carde, Patrice
Publicado 2022

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory...

por Moskowitz, Alison J., Shah, Gunjan, Schöder, Heiko, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Sohail, Samia, Santarosa, Alayna, Capadona, Charisse, Munayirji, Brittney, Kumar, Anita, Lahoud, Oscar, Batlevi, Connie, Hamlin, Paul, Straus, David J., Owens, Colette, Caron, Philip, Intlekofer, Andrew, Hamilton, Audrey, Horwitz, Steven, Falchi, Lorenzo, Johnson, William, Palomba, Lia, Noy, Ariela, Matasar, Matthew, Pongas, Georgios, Salles, Gilles, Vardhana, Santosha, Sanin, Beatriz Wills, Yahalom, Joachim, Dogan, Ahmet, Zelenetz, Andrew, Moskowitz, Craig H.
Publicado 2022

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry

por Fromm, Jonathan, Tang, Claire, Naresh, Kikkeri N.
Publicado 2022

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma

por Kilian, Annika L., Lollies, Anna, Weniger, Marc A., Küppers, Ralf
Publicado 2022

P079: PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by phys...

por Ramos-Cillan, Sergio, Castillo, Eva, Riesco, Miriam, Herroro, Antonio, Pascual, Adriana, Lopez-Garcia, Alberto, Perez, Maria Angeles, Morillo, Daniel, Askari, Alham, Prieto, Elena, Llamas, Pilar, Becares, Javier, Barriocanal, Carla, Del Olmo, Marta, Short, Jorge, Arcos, Javier, Córdoba, Raul
Publicado 2022

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma

por Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David, Mccarten, Kathleen, Horton, Terzah, Cho, Steve, Wu, Yue, Punnett, Angela, Dave, Hema, Henderson, Tara O., Hoppe, Bradford S., Charpentier, Ann-Marie, Keller, Frank G., Kelly, Kara M.
Publicado 2022

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans

por Shakir, Rebecca, Butterworth, Victoria, Ntentas, Georgios, Ramroth, Johanna, Cutter, David
Publicado 2022

Index of Authors

Publicado 2022

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma

por Seifert, Nicole, Reinke, Sarah, Grund, Johanna, Müller-Meinhard, Berit, Engert, Andreas, Bröckelmann, Paul J., Klapper, Wolfram, Altenbuchinger, Michael
Publicado 2022

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients

por Goldkuhl, Christina, Dasu, Alexandru, Bäck, Anna, Enblad, Gunilla, Glimelius, Ingrid, Hall, Annika, Hansson, Lotta, Jerlström., Urban, Johansson, Ann-Sofie, Kahlmeter-Brandell, Jenny, Linderoth, Johan, Palma, Marzia, Rylander, Hillevi, Enmark, Marika, Molin, Daniel
Publicado 2022